Invivyd, Inc.
IVVDNasdaq
$0.74
↓ -5.8%Jul 17 close · end-of-day
Price
1Y↑ +8.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$229.9M
Enterprise Value
$45.8M
P/E
—
P/S
4.1
P/B
1.1
EV/EBITDA
—
PEG
—
FCF Yield
-34.6%
Dividend Yield
—
Revenue (TTM)
$55.9M
Net Income (TTM)
-$77.6M
Free Cash Flow (TTM)
-$79.5M
Gross Margin
—
Operating Margin
-146.4%
Net Margin
-138.9%
ROE
-38.2%
ROIC
-341.9%
Debt / Equity
—
Net Cash
$184.2M
Return 1Y
+2.9%
Company profile
Adagio Therapeutics focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease.
- CEO
- David Hering
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 100
- Headquarters
- Massachusetts
- Website
- invivyd.com
Management & directors
- Allen Robert D. IiiChief Scientific Officer
- Andersen JillChief Legal Officer, Secretary
- Duke William E.Chief Financial Officer
- Green JulieChief Human Resources Officer
- Lee Timothy EdwardChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
IVVD Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$13.7M↑ +21.6%
Diluted EPS-$0.13↓ -7.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2021 | FY2021 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0.00 | $25.4M | $53.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | -$226.9M | -$248.0M | -$212.8M | -$176.9M | -$55.6M |
| Net income | -$38.7M | -$83.4M | -$143.7M | -$226.8M | -$241.3M | -$198.6M | -$169.9M | -$52.5M |
| Diluted EPS | — | — | — | -$5.32 | -$2.23 | -$1.81 | -$1.43 | -$0.30 |
| Operating cash flow | — | — | — | -$184.7M | -$220.0M | -$173.2M | -$170.5M | -$58.1M |
| Free cash flow | — | — | — | -$184.8M | -$221.7M | -$173.8M | -$170.6M | -$58.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | -696.8% | -104.0% |
| Net margin | — | — | — | — | — | — | -669.4% | -98.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.3M | $9.3M | $13.8M | $11.3M | $11.8M | $13.1M | $17.2M | $13.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$49.2M | -$62.3M | -$19.2M | -$16.9M | -$15.1M | -$11.0M | -$12.6M | -$43.1M |
| Net income | -$47.2M | -$60.7M | -$18.4M | -$16.3M | -$14.7M | -$10.5M | -$11.1M | -$41.4M |
| Diluted EPS | -$0.40 | -$0.51 | -$0.14 | -$0.14 | -$0.12 | -$0.06 | $0.02 | -$0.13 |
| Operating cash flow | -$41.6M | -$41.1M | -$37.6M | -$21.1M | -$13.3M | -$8.3M | -$15.5M | -$41.7M |
| Free cash flow | -$41.6M | -$41.1M | -$37.6M | -$21.3M | -$13.3M | -$8.3M | -$15.5M | -$42.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -2175.2% | -670.0% | -139.1% | -149.7% | -127.8% | -84.0% | -73.0% | -313.9% |
| Net margin | -2086.9% | -653.1% | -133.5% | -144.1% | -124.4% | -79.7% | -64.3% | -301.2% |
Company news
Jul 6, 2026
- 14d agoIVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA Approvalstocktwits.com
- 14d agoInvivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDAfinance.yahoo.com
Jul 2, 2026
Jun 29, 2026
Jun 19, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-02-18 | Andersen Jill· Chief Legal Officer, Secretary | Sale | 34,939 | $1.58 | $55,126.75 | filing |
| 2026-02-18 | Green Julie· Chief Human Resources Officer | Sale | 20,964 | $1.58 | $33,077.00 | filing |
| 2026-02-18 | Duke William E.· Chief Financial Officer | Sale | 20,964 | $1.58 | $33,077.00 | filing |
| 2026-02-18 | Lee Timothy Edward· Chief Commercial Officer | Sale | 20,964 | $1.58 | $33,077.00 | filing |
| 2026-02-18 | Allen Robert D. III· Chief Scientific Officer | Sale | 19,392 | $1.58 | $30,596.70 | filing |
| 2026-02-17 | Andersen Jill· Chief Legal Officer, Secretary | Sale | 32,771 | $1.54 | $50,454.23 | filing |
| 2026-02-17 | Green Julie· Chief Human Resources Officer | Sale | 19,663 | $1.54 | $30,273.15 | filing |
| 2026-02-17 | Duke William E.· Chief Financial Officer | Sale | 19,663 | $1.54 | $30,273.15 | filing |
| 2026-02-17 | Lee Timothy Edward· Chief Commercial Officer | Sale | 19,663 | $1.54 | $30,273.15 | filing |
| 2026-02-17 | Allen Robert D. III· Chief Scientific Officer | Sale | 18,189 | $1.54 | $28,003.78 | filing |
| 2026-02-15 | Lee Timothy Edward· Chief Commercial Officer | Option exercise | 99,000 | — | — | filing |
| 2026-02-15 | Allen Robert D. III· Chief Scientific Officer | Option exercise | 99,000 | — | — | filing |
| 2026-02-15 | Green Julie· Chief Human Resources Officer | Option exercise | 99,000 | — | — | filing |
| 2026-02-15 | Duke William E.· Chief Financial Officer | Option exercise | 99,000 | — | — | filing |
| 2026-02-15 | Andersen Jill· Chief Legal Officer, Secretary | Option exercise | 165,000 | — | — | filing |
| 2025-11-19 | MCLAUGHLIN KEVIN F | Buy | 50,000 | $2.50 | $125,000.00 | filing |
| 2025-08-19 | Andersen Jill· Chief Legal Officer, Secretary | Sale | 49,402 | $0.57 | $27,991.17 | filing |
| 2025-08-19 | Lee Timothy Edward· Chief Commercial Officer | Sale | 29,643 | $0.57 | $16,795.72 | filing |
| 2025-08-19 | Duke William E.· Chief Financial Officer | Sale | 29,643 | $0.57 | $16,795.72 | filing |
| 2025-08-19 | Green Julie· Chief Human Resources Officer | Sale | 29,643 | $0.57 | $16,795.72 | filing |
| 2025-08-19 | Allen Robert D. III· Chief Scientific Officer | Sale | 27,420 | $0.57 | $15,536.17 | filing |
| 2025-08-18 | Andersen Jill· Chief Legal Officer, Secretary | Sale | 33,352 | $0.65 | $21,685.47 | filing |
| 2025-08-18 | Lee Timothy Edward· Chief Commercial Officer | Sale | 20,013 | $0.65 | $13,012.45 | filing |
| 2025-08-18 | Duke William E.· Chief Financial Officer | Sale | 20,013 | $0.65 | $13,012.45 | filing |
| 2025-08-18 | Green Julie· Chief Human Resources Officer | Sale | 20,013 | $0.65 | $13,012.45 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.